這集延續了第148集對FDA成立背景的討論，更深入探討FDA多年監管後出現的一些值得深思的問題。 本集內容來自個人和業界經驗分享，提出現象供大家思考，不是評斷對錯。 你可以聽到： 1. 減肥藥「猛建樂」（Mounjaro）與美國的複合藥局（compounding pharmacies）現象 2. FDA法規對創新的潛在阻礙 3. FDA使用者付費制度（如PDUFA）的利益衝突疑慮 4. FDA官員的「旋轉門條款」效應 本集內容提到的BMJ文章： https://bmjgroup.com/fda-staff-leaving-for-industry-jobs-given-behind-the-scenes-lobbying-advice/ 留言告訴我你對這一集的想法： https://open.firstory.me/user/ckssiau1vq5ic082295g8on9d/comments ✎ 留言: podcast.biomeder.com/contact-us 📧 Email: [email protected] 《生醫人生旅歷》podcast.biomeder.com 《BioMeder生醫人網摘》biomeder.com Powered by Firstory Hosting
No persons identified in this episode.
This episode hasn't been transcribed yet
Help us prioritize this episode for transcription by upvoting it.
Popular episodes get transcribed faster
Other recent transcribed episodes
Transcribed and ready to explore now
Before the Crisis: How You and Your Relatives Can Prepare for Financial Caregiving
06 Dec 2025
Motley Fool Money
OpenAI's Code Red, Sacks vs New York Times, New Poverty Line?
06 Dec 2025
All-In with Chamath, Jason, Sacks & Friedberg
OpenAI's Code Red, Sacks vs New York Times, New Poverty Line?
06 Dec 2025
All-In with Chamath, Jason, Sacks & Friedberg
Anthropic Finds AI Answers with Interviewer
05 Dec 2025
The Daily AI Show
#2423 - John Cena
05 Dec 2025
The Joe Rogan Experience
Warehouse to wellness: Bob Mauch on modern pharmaceutical distribution
05 Dec 2025
McKinsey on Healthcare